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ABSTRACT Ligands entering a protein binding pocket essentially compete with water 
molecules for binding to the protein. Hence, the location and thermodynamic properties of water 
molecules in protein structures have gained increased attention in the drug design community. 
Including corresponding data into 3D pharmacophore modeling is essential for efficient high 
throughput virtual screening. Here, we present PyRod, a free and open-source python software 
that allows for visualization of pharmacophoric binding pocket characteristics, identification of 
hot spots for ligand binding and subsequent generation of pharmacophore features for virtual 
screening. The implemented routines analyze the protein environment of water molecules in 
molecular dynamics (MD) simulations and can differentiate between hydrogen bonded waters as 
well as waters in a protein environment of hydrophobic, charged or aromatic atom groups. The 
gathered information is further processed to generate dynamic molecular interaction fields 
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(dMIFs) for visualization and pharmacophoric features for virtual screening. The described 
software was applied to 5 therapeutically relevant drug targets and generated pharmacophores 
were evaluated using DUD-E benchmarking sets. The best performing pharmacophore was 
found for the HIV1 protease with an early enrichment factor of 54.6. PyRod adds a new 
perspective to structure-based screening campaigns by providing easy-to-interpret dMIFs and 
purely protein-based pharmacophores that are solely based on tracing water molecules in MD 
simulations. Since structural information about co-crystallized ligands is not needed, screening 
campaigns can be followed, for which less or no ligand information is available. PyRod is freely 
available at https://github.com/schallerdavid/pyrod. 
INTRODUCTION 
Unliganded protein binding pockets are occupied by water molecules which obligates potential 
ligands to compete with these water molecules for binding to the protein. Hydrogen bonds 
between water and protein need to be broken and replaced water molecules will be released to 
the bulk solvent. This process heavily affects the thermodynamic properties of the system and 
renders water as one of the key elements to understand and promote ligand binding1,2. Several 
approaches (e.g. 3D-RISM3, GIST4) have been developed and employed to estimate the 
enthalpic and entropic contribution of replacing water molecules from protein binding sites 
which proofed to be useful in pinpointing hot spots for ligand binding and in explaining 
structure-activity relationships. Including data from molecular dynamics (MD) simulations was 
found to improve such predictions5. However, researchers at GSK conclude in a recent 
perspective6 that many studies utilizing water-based methods are of retrospective nature and 
several results could have been obtained by simply looking at the atomistic models, e.g. growing 
a ligand into a hydrophobic protein pocket will most likely increase the affinity. 
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Pharmacophores describe electrostatic and steric features needed for a molecule to bind to a 
desired drug target and can be employed in a truly prospective fashion in efficient high-
throughput virtual screening campaigns to identify novel active entities7. Recently, MD 
simulations were analyzed to generate so called water pharmacophores8. The researchers 
analyzed the thermodynamic characteristics of hydration sites in binding pockets of several drug 
targets and were able to translate this information into pharmacophores that were successfully 
evaluated in retrospective screening campaigns. However, the method makes use of commercial 
software and is not available for public use. 
Here, we present PyRod, a free and open-source python software that was built to translate the 
highly complex, but important information from MD simulations into simplistic and highly 
efficient pharmacophore models suitable for virtual screening. PyRod supports the 4 major 
forcefields CHARMM9, AMBER10, GROMOS11 and OPLS12 granting maximum flexibility for 
the user in choosing the simulation package for generating MD simulation data. We applied 
PyRod to 5 important drug targets and evaluated its capability to generate successful 
pharmacophores for virtual screening. 
IMPLEMENTATION 
PyRod is available as open-source software written in python 313 and employs the external 
packages MDAnalysis14, NumPy15 and SciPy16. It is composed of several components that can 
be executed individually via self-explainable config files (Figure 1A). Additionally, a trajectory 
pharmacophore combo config file is provided which enables a one-step-execution of several 
tasks.  
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Figure 1: (A) Workflow diagram of PyRod. Each box represents a single component of PyRod 
that can be executed separately or in combination using the trajectory pharmacophore combo. 
(B) Depiction of the exclusion volume sphere generation algorithm. Top: The neighborhood 
within 0.5 Å and 1 Å of each grid point is analyzed. Bottom: Only grid points with a shape score 
less than 1 are depicted, representing an area with low water occupancy, e.g. within the protein. 
Grid points with a shape score of 1 or higher are not depicted and would fall into the white area 
corresponding to a potential protein binding pocket. Grey grid points are at the grid boundaries 
and are not considered for exclusion volume placement. The described algorithm favors 
exclusion volume spheres with a maximum number of neighbors within 0.5 Å, but a minimal 
number of neighbors within 1 Å, and would generate 3 exclusion volumes in this example in the 
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order described by the numbers. (C) Depiction of the iterative chemical feature generation. (D-F) 
Examples for hydrophobic interaction (HI) scores scaled by buriedness. Each depiction 
represents a water oxygen with 4 hydrophobic atoms within 5 Å resulting in different HI scores. 
The buriedness algorithm evaluates the hydrophobic atom positions by calculating angles with 
the water oxygen as vertex. (D) Water molecule is not buried. (E) Water molecule is buried 
between two hydrophobic centers. (F) Water molecule is buried between 4 hydrophobic centers. 
Test Grid. This component facilitates the identification of parameters for proper grid 
placement allowing the user to focus on the protein area of interest in later trajectory analysis. 
The x, y and z center parameters are used to define the center of the grid which can be retrieved 
from e.g. a central atom in the binding pocket with coordinates stored in the topology file or by 
employing pocket detection algorithms externally. The x, y and z edge length parameters define 
the size of the grid and are usually set between 20 and 30 Å, but can be set higher if the whole 
protein surface should be explored.  The test grid will be saved in pdb format with grid points as 
pseudo atoms. This file can then be visualized together with the topology file to improve 
parameters if required. 
Trajectory Analysis. The implemented routines analyze the protein environment of water 
molecules in MD simulations to predict favorable sites for chemical feature placement, i.e. 
hydrogen bond, ionizable, hydrophobic and aromatic interactions. The employed heuristic 
scoring functions do not calculate thermodynamic properties, but instead estimate favorable 
regions for chemical feature placement in each frame based on fast-to-calculate geometric 
descriptors. Since scoring is only performed in presence of water, PyRod favors regions with 
stable water molecules whose replacement by ligands will result in a gain of entropy. Chemical 
feature scores are summated throughout the trajectory in a NumPy15 representation of the 3D 
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grid whose position and size can be determined by using the test grid component. Spacing 
between grid points is fixed to 0.5 Å. MDAnalysis14 is employed as topology and trajectory 
reader supporting various molecular data formats. Residue and atom names are standardized 
enabling the support of widely used force fields CHARMM9, AMBER10, GROMOS11 and 
OPLS12. The gathered information is transformed for each chemical feature type into dynamic 
molecular interaction fields (dMIFs) and can be saved in density map format (kont, cns, xplor) 
for visualization of pharmacophoric binding pocket characteristics. The name dMIF was chosen, 
since the generated maps introduce dynamics to the concept of molecular interaction fields 
(MIFs), an established tool in modern drug discovery describing the interaction energy between a 
probe and a molecular target. For an extensive review on molecular interaction fields we would 
like to refer the reader’s attention to a publication by Artese and co-authors17. 
In a first step, the protein is analyzed for atoms and atom groups corresponding to potential 
chemical feature interaction partners (supporting information Tab. S1), e.g. oxygen atoms of the 
aspartate carboxylate group are hydrogen bond acceptors and part of a negatively charged group 
if deprotonated. Next, water molecules are localized in each trajectory frame and their protein 
environment is analyzed for the previously defined chemical feature interaction partners. If 
certain geometrical criteria are met (supporting information Tab. S2), grid points within 1.41 Å 
(radius of water molecule18) of the water molecule are identified using fast KDTree19 routines 
from SciPy16 and scored according to the chemical feature type. 
Water molecules have two lone pairs and two hydrogens allowing the formation of hydrogen 
bond as acceptor as well as donor. If water molecules at a certain position are half of the time 
hydrogen bonded to the protein as donor and half of the time as donor and acceptor, this could 
indicate two different protein conformations which is important to pharmacophore generation. 
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Hence, hydrogen bonding interactions are split into 6 categories, i.e. single hydrogen bond donor 
(HD), single hydrogen bond acceptor (HA), double hydrogen bond donor (HD2), double 
hydrogen bond acceptor (HA2) and mixed hydrogen bond donor/acceptor (HDA). Water 
molecules involved in more than two hydrogen bonds with the protein are treated as trapped 
water (TW). Such water molecules are typically deeply buried in the protein making them barely 
accessible for ligands and only very few ligands would be able to fulfill the geometric criteria to 
replace the water molecule sufficiently. Thus, trapped waters are not considered for later 
chemical feature generation. However, trapped waters can be of interest in later screening hit 
selection, since they might serve as bridge between protein and ligand. Water molecules near 
metal ions (e.g. Zn2+, Mn2+) are treated as hydrogen bond acceptors and are included in the 
hydrogen bond count to identify trapped waters. Positions of the protein interaction partners are 
stored to allow later chemical feature generation with directionality. Gathered hydrogen bond 
scores are transformed into easy-to-interpret occupancies, e.g. a HA score of 15 means that in 15 
% of the frames there was a water molecule at this position being involved as a single hydrogen 
bond acceptor with the protein. 
Positive (PI) and negative ionizable interactions (NI) are also scored as occupancies but are 
additionally scaled by distance, since they represent long range interactions whose energy decays 
with increasing distance. Furthermore, PI and NI quench each other. A PI score of 80 can 
describe very different situations, e.g. there was a water molecule in 80 % of the frames in the 
optimal distance to 1 PI partner but no NI partner or in 40 % of the frames in the optimal 
distance to 3 PI partners and 1 NI partner. 
Aromatic interactions (AI) show a rather complex geometry involving several angles and 
distances (supporting information Tab. S2). Additionally, in contrast to hydrogen bond and 
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ionizable interactions, water molecules will not necessarily accumulate at a favorable position 
for potential ligand interaction partners. Thus, grid points close to such water molecule are 
evaluated individually to satisfy the AI geometry criteria and receive an individually distance 
scaled occupancy score. Idealized positions for potential interaction partners are stored for later 
feature generation with directionality. 
Cation-π interactions are also recorded by the implemented routines and included in PI and AI 
scores, e.g. water molecules close to the aromatic ring of a phenylalanine will be scored for PI 
and water molecules close to the positively charged amine of a lysine will be scored for AI. 
However, they receive a dedicated heuristic scoring function differing from earlier presented PI 
and AI scoring (supporting information Tab. S2). 
Regions for potential hydrophobic interactions (HI) are identified by counting hydrophobic 
atoms in vicinity of each water molecule. This crude atom count is additionally scaled by 
buriedness to highlight regions with water molecules deeply enclosed in a hydrophobic pocket 
(Figure 1D-F). In a first step, positions of hydrophobic atoms within 5 Å of the water oxygen are 
collected. If only one hydrophobic atom was identified, the hydrophobic score is 1 and no further 
calculation is performed. Otherwise, hydrophobic atom positions are analyzed to estimate the 
buriedness of the water molecule as follows. Two hydrophobic atom positions are determined 
that form the maximal angle with the water oxygen position as vertex, e.g. two hydrophobic 
atoms with a water molecule exactly in between would lead to an angle of 180 degrees. If this 
maximal angle is less than 30 degrees, the algorithm is terminated, and the hydrophobic score 
remains 1 (Figure 1D). Such situation corresponds to a geometry, where a water molecule is 
close to multiple hydrophobic atoms but not buried. Otherwise, the hydrophobic score is 
increased by 1, both hydrophobic atom positions are marked as accepted and one of the two 
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hydrophobic atom positions forming the maximal angle is randomly selected as reference 
position for further processing. The remaining hydrophobic atom positions are analyzed in an 
iterative fashion as follows. First, the hydrophobic atom position is identified that forms the 
maximal angle with the reference position and the water oxygen position as vertex. Next, this 
hydrophobic atom position is evaluated for angles formed with the already accepted positions 
and the water oxygen as vertex. If none of the formed angle is smaller than 30 degrees, the 
hydrophobic score is increased by 1 and the evaluated position is marked as accepted position. 
Otherwise, this position is ignored. This procedure is repeated until all hydrophobic atom 
positions were evaluated resulting in a hydrophobic score that is strongly dependent on the 
hydrophobic buriedness of the water molecule. However, highly hydrophobic regions may not be 
sampled well by water molecules and will be scored less frequently and consequently may 
receive a lower absolute HI score. Hence, a normalized score is provided as well (HInorm) which 
reports the average hydrophobic score per occurrence, e.g. a HInorm score of 5.3 means that when 
a water molecule occurred at this position the near grid points retrieved on average a HI score of 
5.3. 
Exclusion Volume Spheres. During trajectory analysis the presence of water is recorded to 
generate a shape dMIF. It is used in this component to place exclusion volumes limiting the 
binding pocket volume in later pharmacophores with the following algorithm (Figure 1B). Grid 
points must have a shape score less than 1 (corresponding to water occupancy of 1 %, can be 
changed by the user) and are sorted for the number of neighbors (grid points with a shape score 
less than 1) within 1 Å. Next, each grid point is evaluated as center of an exclusion volume 
starting with the grid point with the lowest number of neighbors within 1 Å. Grid points with 
very few neighbors usually correspond to protein side chains pointing inside the binding pocket 
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and are prioritized by the algorithm. To be accepted as the center of an exclusion volume, a grid 
point must not be at the grid boundaries, must have exactly 7 neighbors within 0.5 Å but less 
than 33 neighbors within 1 Å ensuring that exclusion volumes are placed only at the interface of 
protein and water but not too close to the chemical features and finally, must not be within 4 Å (2 
Å if restrictive mode is enabled) of an already generated exclusion volume. 
Chemical Features. A novel algorithm was implemented translating dMIFs into 
corresponding chemical features for pharmacophore virtual screening (Figure 1C). First, all grid 
points become part of a pool of available grid points for the respective chemical feature 
generation. Next, the grid points with the highest feature score in the grid point pool are 
determined. If this search results in a single grid point, its position will be used as center of the 
chemical feature. The tolerance radius of that chemical feature is identified by iteratively 
increasing the search radius (minimum=1.5 Å) from the feature center in 0.5 Å steps. If the 
feature score of a grid point within the search radius is below half of the current highest feature 
score, the search is stopped, and the current search radius will be used as tolerance radius for the 
chemical feature. If multiple grid points share the highest feature score in the grid point pool, the 
following procedures are performed to select a single grid point as feature center. Tolerance radii 
are calculated for each of the considered grid points. The grid point with the highest tolerance 
radius will be used as center of the chemical feature. If multiple grid points share the highest 
tolerance radius, the sum of feature scores of the grid points within the tolerance radius is 
calculated and the grid point with the highest sum of feature scores is selected as feature center. 
If this procedure does not lead to the selection of a single grid point, a random pick of the 
remaining grid points is performed. Grid points within the tolerance radius of a chemical feature 
must not be part of an already generated chemical feature of the respective chemical feature type. 
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This criterion prevents overlap of chemical features within chemical feature types. In case of 
hydrogen bond and aromatic interactions, recorded positions of interaction partners are clustered 
by searching for the interaction partner position with the most neighboring interaction partner 
positions within 1.5 Å. This procedure allows the generation of chemical features with 
directionality. Finally, grid points within the tolerance radius of the feature center are removed 
from the pool of available grid points and a new iteration is started. The chemical feature 
generation is terminated if 20 chemical features (can be changed by the user) of the respective 
chemical feature type were generated or if the highest feature score of the grid point pool 
decreases below 1.   
Pharmacophores. The output of exclusion volume and chemical feature generation is merged 
and saved as a single “super pharmacophore” containing all previously generated chemical 
features and exclusion volumes. Additionally, a pharmacophore can be saved containing only the 
highest ranked features for each chemical feature class as specified by the user, e.g. 20 highest 
scored hydrogen bonding features and 5 highest scored hydrophobic features. Currently, PyRod 
supports LigandScout20 and pdb-like pharmacophore formats. The pdb-like pharmacophore file 
uses the residue name column to specify the chemical feature type and aims at providing a 
pharmacophore format readable by human and various molecular modeling softwares. However, 
directionality is not included in the pdb-like pharmacophore format. 
Combinatorial Library. The generated “super pharmacophores” can contain more than 100 
chemical features, which remains computationally challenging to screen also with the current 
progress in CPU performance. Thus, reducing the number of chemical features is key to enable 
fast high-throughput virtual screening. This component facilitates the generation of a 
combinatorial library of pharmacophores with a specified number of chemical features as defined 
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by the user. First, the user preselects chemical features of interest in LigandScout20 and saves this 
pharmacophore for combinatorial processing. Chemical features that should be present in every 
generated pharmacophore have to be set mandatory, whereas chemical features that should be 
added in a combinatorial fashion have to be set optional. Next, the user can specify the limits for 
minimal and maximal number of chemical features in the config file, i.e. number of independent 
chemical features, number of hydrogen bonding features, number of ionizable features, number 
of aromatic features and number of hydrophobic features. Prior to library generation the user will 
be informed about the number of possible pharmacophores and prompted for execution. To 
further limit the library size each pharmacophore is evaluated for the following rules, i.e. (i) 
ionizable and hydrophobic features should not appear within 3 Å, (ii) different hydrogen bonding 
features should not be present within 1.5 Å, since such situation implies two different protein 
conformations, (iii) different ionizable features should not be present within 3 Å and (iv) 
hydrogen bonding features of HA2, HD2 and HDA are not allowed to be split. PyRod also 
provides a customizable pharmacophore evaluation script written in python performing receiver 
operatic characteristics analysis with LigandScout20. 
dMIF Excess. Selectivity within a protein family as well as the occurrence of mutation-
induced resistance remain a major challenge in modern drug discovery21,22. It would be desirable 
to exploit such minor differences in protein binding pockets. Thus, this component enables the 
comparison of dMIFs between closely related proteins by generating dMIF excess maps 
visualizing the excess of one system over the other. 
TEST SYSTEMS 
PyRod performance was evaluated on 5 important drug target test systems, i.e. cyclin-
dependent kinase 2-cyclin A complex (CDK2, 5if123 (1)), HIV-1 protease (HIV1P, 1nh024 (2)), 
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estrogen receptor alpha (ERα, 1xpc25 (3)), dopamine D3 receptor (D3R, 3pbl26 (4)) and 
adenosine A2A receptor (A2AR, 5iu4
27 (5)). Protein selection was based on therapeutic relevance, 
availability of benchmarking sets from DUD-E28 and crystal structures from PDB29 as well as 
protein family diversity. 
System Setup. Crystal structures were retrieved from PDB29 and prepared in MOE 201530 as 
follows. Ligands were deleted as well as water more than 5 A away from the protein. Errors were 
corrected with the Structure Preparation tool. The low resolution D3R structure 3pbl misses a 
sodium ion that is known to be crucial for inactive class A GPCR states31. Hence the sodium ion 
and 6 coordinating water molecules were transferred from the high resolution structure of δ 
opioid receptor (4n6h32) into the D3R system. Chain breaks were capped with ACE and NME. 
Protonation states were assigned using Protonate 3D tool at pH 7. Non-membrane proteins 
(CDK2, HIV1P and ERα) were solvated in a cubic box with TIP4P water, 0.15 M NaCl and 10 Å 
padding using Maestro 11.333. Membrane proteins (A2AR and D3R) were embedded in a POPC 
bilayer according to the orientation provided by the PPM server34 and solvated in an 
orthorhombic box with TIP4P water, 0.15 M NaCl and 10 Å padding.  
Molecular dynamics simulation. Simulations were performed with Desmond 5.135 and the 
OPLS 200536 forcefield on a Nvidia GeForce GTX 1070 graphics card. Minimization and 
equilibration were performed with default settings. 10 replications of 10 ns simulation were 
performed for each system with periodic boundary conditions in NPT ensemble. The temperature 
was retained at 300 K using the Nose-Hoover thermostat, and the pressure at 1.01325 bar using 
the Martyna-Tobias-Klein barostat. Coordinates were saved every 5 ps resulting in 2000 frames 
per simulation. Trajectories were additionally processed in VMD 1.9.237, i.e. the protein was 
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centered in the water box by using the pbc tool and trajectories were aligned on the protein 
backbone heavy atoms using the RMSD Trajectory tool. 
The CDK2 system (5if123) was also simulated with OpenMM 7.2.238 on a Nvidia GeForce 
GTX 1070 graphics card employing the Amber forcefield ff14SB10 with TIP4P-Ew water model 
to test the effect of restraining heavy atoms. The same prepared protein structure was used as for 
Desmond simulations described above. The protein was solvated in a cubic water box with 10 Å 
padding and 0.15 M NaCl. The Particle Mesh Ewald method was used to calculate long range 
electrostatic interactions with a 10 Å cutoff and all bonds involving hydrogens were constrained 
in length. Langevin dynamics were performed at 300 K with 2 fs time step. 10 replications of 10 
ns simulations were performed with periodic boundary conditions and NPT ensemble. 
Coordinates were saved every 5 ps resulting in 2000 frames per simulation. The simulations 
were performed with and without a custom force of 5 kcal restraining protein heavy atoms at 
their initial position. Resulting trajectories were processed in VMD37 as already described. 
PyRod. Grid parameters were adjusted using the test grid component to center the grid in the 
binding site. Grids were cubic with edge lengths of 20 Å for ERα and CDK2, 25 Å for D3R and 
HIV1P and 30 Å for A2AR. Trajectories were processed with PyRod 0.7.1 using last 5 ns of each 
replication resulting in 10,000 frames for analysis of each system with default settings. 
Generated dMIFs were visualized and analyzed in LigandScout 4.220 to preselect pharmacophore 
features according to feature scores and their arrangement in the binding pocket. Selected 
chemical features were subjected to combinatorial processing with the combinatorial library 
component of PyRod. Chemical feature limits for each target can be found in the supporting 
information (Tab. S3). 
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Pharmacophore screening. The ligand benchmarking sets with actives and decoys for CDK2, 
HIV1P, ERα, D3R and A2AR were retrieved from DUD-E server28 in SMILES format. For 
CDK2, ERα, D3R and A2AR 25 conformations were generated per molecule with iCon as 
implemented in LigandScout 4.220. For HIV1P 200 conformations were generated per molecule, 
since the active set primarily contains peptidomimetics with many rotatable bonds. These 
databases were used for pharmacophore evaluation in LigandScout 4.220 employing receiver 
operating characteristic (ROC) curves. 
RESULTS & DISCUSSION 
CDK2. The ATP binding pocket of CDK2 is a well characterized site for inhibition with a 
plethora of crystal structures deposited in the PDB. The most frequently observed interactions 
include hydrogen bonds formed with the backbone of residues E81 and L8339. Concordantly, 
PyRod identified a hydration site at which water molecules act as single hydrogen bond donor to 
the backbone oxygen of E81 in 63 % of all frames (Figure 2B).  Besides being involved in a 
single hydrogen bond, these water molecules are also in a very hydrophobic environment (HI 
score=420, HInorm score=5.85). These characteristics render this hydration site as an essential 
position for ligand binding, since replacing restrained water molecules from a hydrophobic 
pocket by a corresponding ligand moiety should be beneficial for the entropy and enthalpy of the 
system. Adjacent to E81 are further hydration sites at which water molecules are involved in 
hydrogen bonds with the backbone of L83 in 40 % of the frames as single donor, in 19 % of the 
frames as single acceptor and in 15 % of the frames as mixed donor and acceptor (Figure 2B). 
Likewise, these hydration sites lie in a hydrophobic environment (HI score=180-350, HInorm 
score=3.5-6.25) highlighting these positions for additional ligand interactions. Several hotspots 
were identified for placing positive ionizable groups, i.e. at the interface of D145 and F80 as well 
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as next to D86 with PI scores of 70 and 25 respectively, and aromatic moieties, i.e. close to the 
salt bridge formed by K33 and D145 as well as adjacent to F80 with AI scores of 45 and 70 
respectively (Figure 2C). A hydrophobic band with HI scores ranging from 100 to 300 is 
spanning the binding pocket that resulted in the generation of 6 hydrophobic features (Figure 
2C). In total 15 chemical features were selected based on the corresponding feature score and 
their arrangement in the binding pocket (Figure 2D). By employing the combinatorial library 
component of PyRod, these features were combined to 816 pharmacophores with 3 to 5 chemical 
features. The hydrogen bonding donor feature pointing towards the backbone oxygen of E81 was 
selected to be present in every pharmacophore. Further parameters can be found in the 
supporting information (Tab. S3). Using LigandScout20 all pharmacophores were screened 
against an active set retrieved from the DUD-E28 database and additionally evaluated against 
decoys if 5 % of the actives were found. Hit lists were evaluated for early enrichment factor 
(EF1) and plotted against found actives to select pharmacophores of interest (Figure 2E). The 
most selective pharmacophore (EF1=30.3) consists of 2 hydrophobic features, 1 hydrogen bond 
donor and 1 hydrogen bond mixed donor/acceptor (Figure 2F). 
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Figure 2: (A) Shape dMIF of CDK2 (cutoff 1) with exclusion volumes present in each generated 
pharmacophore. (B, C) Characterized binding pocket with dMIFs for single hydrogen bond 
donor (green, cutoff 38), single hydrogen bond acceptor (red, cutoff 17), mixed hydrogen bond 
donor/acceptor (cyan, cutoff 14), positive ionizable (blue, cutoff 27), aromatic interaction 
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(magenta, cutoff 36) and hydrophobic interaction (yellow, cutoff 100). Cutoffs were chosen to 
visualize decision making in subsequent pharmacophore feature selection.  (D) Selected 
pharmacophore features based on chemical feature score and arrangement (green arrow – 
hydrogen bond donor, red arrow – hydrogen bond acceptor, yellow sphere – hydrophobic 
interaction, blue star – positive ionizable, blue ring plane – aromatic interaction). (E) 
Performance evaluation of pharmacophore library. (F) Pharmacophore with best early 
enrichment factor (EF1;5;10;100: 30.3;30.3;30.3;30.3, AUC1;5;10;100: 0.99;0.99;0.88;0.54). 
D3R. Currently, only a single crystal structure of D3R is available. However, this target was 
studied extensively with many known ligands stored in public data bases. A key interaction 
shared across all aminergic GPCRs is a charged interaction to an aspartate in the orthosteric 
binding pocket40. PyRod located several hydration sites with water molecules pointing as single 
hydrogen bond donor towards D110 in 35-50 % of the frames with PI scores between 35 and 50 
(Figure 3B-C). Additionally, we found 2 sites with water molecules acting as hydrogen bond 
acceptor with a HA score of 20 next to the backbone nitrogen of I183 and to the imidazole ring 
of H349. Hydrophobic hotspots (HI score=140-225, HInorm score=3.80-4.25) were identified 
close to F345 and above D110 as well as sites for aromatic interactions (AI score=15) next to 
F345. In total, 16 chemical features were selected and combined to 2441 pharmacophores with 3 
to 5 independent features (Figure 3D). Further parameters can be found in the supporting 
information (Tab. S3). The best performing pharmacophore (EF1=7.7) consists of 1 hydrophobic 
feature, 1 hydrogen bond acceptor and 1 positive ionizable feature (Figure 3E-F).  
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Figure 3: (A) Shape dMIF of D3R (cutoff 1) with exclusion volumes present in each generated 
pharmacophore. (B, C) Characterized binding pocket with dMIFs for single hydrogen bond 
donor (green, cutoff 36), single hydrogen bond acceptor (red, cutoff 19), positive ionizable (blue, 
cutoff 33), aromatic interaction (magenta, cutoff 14) and hydrophobic interaction (yellow, cutoff 
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160). Cutoffs were chosen to visualize decision making in subsequent pharmacophore feature 
selection. (D) Selected pharmacophore features based on chemical feature score and arrangement 
(green arrow – hydrogen bond donor, red arrow – hydrogen bond acceptor, yellow sphere – 
hydrophobic interaction, blue star – positive ionizable, blue ring plane – aromatic interaction). 
(E) Performance evaluation of pharmacophore library. (F) Pharmacophore with best early 
enrichment factor (EF1;5;10;100: 7.7;3.3;2.3;2.0, AUC1;5;10;100: 0.92;0.94;0.93;0.58). 
HIV1P. The protease of HIV1 is a well characterized target for inhibiting virus replication. 
Mature HIV1P exists as a homodimer with two aspartates (D25, D25’) in the catalytic center. 
The hydroxyl group of approved drugs mimics a water molecule present in the transition state 
and results in inhibition of the protease41. PyRod located two hydration sites between the two 
catalytic aspartates with HD2 scores of 40 and a PI score of 110 (Figure 4B). Hydrophobic 
pockets are symmetrically distributed around the catalytic center resulting in several 
hydrophobic features (HI score=120-270, HInorm score=2.80-4.90). PyRod also found the 
hydration site (Figure 4C) between the backbone nitrogens of I50 and I50’ where water 
molecules are bound as double or single hydrogen bond acceptor (HA2 score=5, HA score=17). 
This water molecule is observed frequently in inhibitor-bound crystal structures serving as bridge 
between ligand and protein, but can also be replaced41. Finally, PyRod identified a hydration site 
next to D29 and D30 with water molecules acting as double hydrogen bond acceptor (HA2 
score=6), single hydrogen bond acceptor (HA score=15) or mixed hydrogen bond donor/acceptor 
(HDA score=27). A single hydrogen bond acceptor feature was chosen at this position to 
represent all 3 observed water conformations (Figure 4D). 588 pharmacophores were generated 
by combining 15 pharmacophore features. The double hydrogen bond donor feature was selected 
to be present in every pharmacophore. Further parameters can be found in the supporting 
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information (Tab. S3). The best performing pharmacophore (EF1%=54.6) consists of 3 
hydrophobic features 2 hydrogen bond donors and 2 hydrogen bond acceptors (Figure 4E-F). 
 
Figure 4: (A) Shape dMIF of HIV1P (cutoff 1) with exclusion volumes present in each 
generated pharmacophore. (B, C) Characterized binding pocket with dMIFs for double hydrogen 
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bond donor (dark green, cutoff 35), positive ionizable (blue, cutoff 90), hydrophobic interaction 
(yellow, cutoff 110), single hydrogen bond acceptor (red, cutoff 13), double hydrogen bond 
acceptor (dark red, cutoff 4) and mixed hydrogen bond donor/acceptor (cyan, cutoff 26). Cutoffs 
were chosen to visualize decision making in subsequent pharmacophore feature selection. (D) 
Selected pharmacophore features based on chemical feature score and arrangement (green arrow 
– hydrogen bond donor, red arrow – hydrogen bond acceptor, yellow sphere – hydrophobic 
interaction, blue star – positive ionizable). (E) Performance evaluation of pharmacophore library. 
(F) Pharmacophore with best early enrichment factor (EF1;5;10;100: 54.6; 54.6; 54.6; 54.6, 
AUC1;5;10;100: 1.00;1.00;0.93;0.54). 
ERα and A2AR. Estrogen receptor alpha and adenosine A2A receptor represent 2 test cases for 
which pharmacophore generation based on water dynamics was not successful. ERα contains a 
hydrophobic pocket25 that is collapsing upon unrestrained molecular dynamics simulation. This 
ultimately leads to the placement of exclusion volumes at a position where co-crystallized 
ligands bind (Figure 5A). Agonists and antagonists of A2AR share two key interactions with 
F168 and N25342. The aromatic interaction with F168 is completely absent in the AI dMIF, since 
F168 is very flexible in the unbound state and adapts a conformation differing from the ligand 
bound state (Figure 5B). Also, N253 and E169 leave the ligand bound conformation quickly 
upon initiating unrestrained simulations and do not frequently interact with water molecules at 
positions known from ligand interaction with N253.  
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Figure 5: (A) Shape dMIF of ERα (cutoff 1) with an exclusion volume placed at a position 
where co-crystallized ligands bind. (B) Characterized binding pocket of A2AR with dMIFs for 
hydrogen bond donor (green, cutoff 40), single hydrogen bond acceptor (red, cutoff 40), 
aromatic interaction (magenta, cutoff 32) and hydrophobic interaction (yellow, cutoff 160). 
Essential key interactions known from co-crystallized ligands are not represented in the dMIFs 
(green arrow – hydrogen bond donor, red arrow – hydrogen bond acceptor, blue ring plane – 
aromatic interaction, yellow sphere – hydrophobic interaction). 
Discussion. An important decision to make when using PyRod is the MD simulation length. 
To estimate the equilibration process of water molecules in protein binding pockets, the change 
of water occupancy in trajectory bins of 50 frames was analyzed for each test system and plotted 
together with the RMSD of protein heavy atoms (supporting information Fig. S1). All test 
systems in this study were equilibrated within first 5 ns of unrestrained MD simulation. 
However, this may be different for other systems. Interestingly, these plots indicate a 
synchronous equilibration of protein and water rendering the protein RMSD an easy-to-use 
descriptor to estimate equilibration times of water molecules in protein binding pockets. The 
total simulation length was restricted to 10 ns for each replication to reduce computational costs 
 24 
and to sample protein conformations close to the crystallographic structure. Replications were 
performed to expand sampling of protein conformations without introducing artifacts from a 
single long MD simulation stuck in a local minimum43. 
Best PyRod pharmacophores of CDK2, D3R and HIV1P outperform the docking program 
DOCK 3.6 when comparing early enrichment factors (EF1) with the DUD-E benchmark28 
(supporting information Tab. S4). However, PyRod pharmacophores could not be generated for 
A2AR and ERα, since both targets quickly leave the ligand-bound conformation upon 
unrestrained MD simulation. Although restraining the protein heavy atoms is tempting, this 
procedure would neglect the contribution of the protein to the entropy of the system44. When 
restraining heavy atoms of the CDK2 system we observed many more stable hydration sites with 
overall higher feature scores, which may hinder prioritization of important chemical features 
(Figure 6). Instead of restraining the protein in MD simulations, it might be an option in such 
situation to employ methods that generate pharmacophores based on the static structure45,46. 
 
Figure 6: Effect of restraining protein heavy atoms on the binding pocket hydration sites of the 
CDK2 system. Generated dMIFs for hydrogen bonding interactions (HB) differ significantly 
between simulations with restrains on protein heavy atoms (yellow) and without (blue). HB 
 25 
dMIFs show areas with a HB score of at least 90 % of the maximal HB score (A) and at least 50 
% of the maximal HB score (B). 
An important difference between the already published water pharmacophore method8 and our 
PyRod approach is the number of generated pharmacophores. The water pharmacophore method 
was designed to generate a single pharmacophore in a highly automated fashion. Although 
retrospectively successful with 4 out of 7 targets, it needs to be shown that the parameters and 
cutoffs trained on the test systems also succeed in a prospective study on a completely different 
target. PyRod does not generate a single pharmacophore for virtual screening, but a 
combinatorial library. This agrees with the fact that different ligands can show different 
interaction patters for the same binding pocket. However, it would be desirable to develop only 
few diverse pharmacophore models with PyRod without knowledge of any ligand data. 
Prospective studies are on the way and the only possibility to proof the usefulness of PyRod in 
such situation. Nevertheless, we are confident that we would have been able generate successful 
pharmacophores by only analyzing dMIFs and selecting features for CDK2 and HIV1P. 
CONCLUSION 
In this study we could show that water dynamics from MD simulations can be used to generate 
highly usable 3D pharmacophore models for virtual screening. Employing the free and open-
source software PyRod we were able to successfully describe pharmacophoric binding pocket 
characteristics and generate pharmacophores for three pharmaceutically relevant drug targets. 
The early enrichment factors from the best performing models range from 7.7 for D3R to 54.6 
for HIV1P. Additionally, we found that restraining protein heavy atoms dramatically affects the 
water dynamics in the binding pocket hindering hot spot identification for ligand binding in 
water-based methods. 
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